Drug Profile
Research programme: cancer therapeutics - Evotec SE/The Ohio State University Comprehensive Cancer Center
Latest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; The Ohio State University Comprehensive Cancer Center
- Developer Evotec SE; The Ohio State University Comprehensive Cancer Center
- Class
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Cancer in Germany
- 22 Dec 2014 Evotec AG and The Ohio State University Comprehensive Cancer Center enters into a collaboration to develop therapeutics for Cancer
- 22 Dec 2014 Early research in Cancer in Germany (unspecified route)